Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Combretastatin A-4
Names | |
---|---|
Preferred IUPAC name
2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethen-1-yl]phenol | |
Other names
Combretastatin A4
CA-4 1-(3,4,5-Trimethoxyphenyl)-2-(3′-hydroxy-4′-methoxyphenyl)ethene 3,4,5-Trimethoxy-3′-hydroxy-4′-methoxystilbene | |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL |
|
ChemSpider |
|
ECHA InfoCard | 100.159.667 |
PubChem CID
|
|
UNII | |
| |
| |
Properties | |
C18H20O5 | |
Molar mass | 316.34 g/mol |
Melting point | 116 °C (241 °F; 389 K) |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Combretastatin A-4 is a combretastatin and a stilbenoid. It can be isolated from Combretum caffrum, the Eastern Cape South African bushwillow tree or in Combretum leprosum, the mofumbo, a species found in Brazil.
Function
Tubulin represents a potent target in cancer chemotherapy, given its role in cell division. Combretastatin is a naturally occurring well known tubulin polymerization inhibitor. Combretastatin A-4 comes in two stereoisomers (cis (shown top right), and trans); The cis form binds much better to the 'colchicine' site on tubulin to inhibit polymerization.
Derivatives
Combretastatin A-4 is the active component of combretastatin A-4 phosphate, a prodrug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis.
A large number of synthetic derivatives have been reported, including beta-lactam based compounds.
See also
- Ombrabulin, a combretastatin A-4 derivative in clinical trials for treatment of cancer
Hydroxystilbenes and their glycosides (monomeric forms)
| |||||||||
---|---|---|---|---|---|---|---|---|---|
O-methylated |
|
||||||||
carboxylated | |||||||||
other acylations | |||||||||
Glycosides |
|
||||||||
Oligomeric forms |